Birte Glenthøj
Biographic Data
| ID | 7389477 |
|---|---|
| NAME | Birte Glenthøj |
| GIVEN NAMES | Birte |
| FAMILY NAME | Glenthøj |
| SIGNATURE | GLENTHØJ B |
| AFFILIATIONS | Glostrup Hospital |
| ORCID | 0000-0003-3056-7262 |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 6 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2018 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia
Our results indicate that pathways to functional outcomes are specific for different domains of real-life functioning and that negative symptoms and social cognition mediate the impact of neurocognitive deficits on different domains of functioning. Our results suggest that both negative symptoms and social cognition should be targeted by psychosocial interventions to enhance the functional impact of neurocognitive remediation
European Validation of the Self-Evaluation of Negative Symptoms (SNS)
In a large European multicentric sample, this study demonstrated that the SNS has: (1) good psychometric properties with good convergent and divergent validities; (2) a five-factor latent structure; (3) an association with patients' functional outcome; and (4) the capacity to identify subjects with negative symptoms that is close to the BNSS and superior to the PANSS negative subscale
Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the Amend Trial Protocol
[ClinicalTrials.gov], identifier [NCT04789915]
Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
Patients treated with aripiprazole improved on negative symptoms, which was not the case for patients treated with amisulpride. This may point to a general effect of a partial D2 receptor agonist on negative symptoms in patients with first-episode psychoses. There was, however, no improvement in cognitive functions
No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis—A Randomized Clinical Trial
ClinicalTrials.gov, identifier NCT02098408
Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers
Progressive loss of brain tissue is seen in some patients with schizophrenia and might be caused by increased levels of glutamate and resting cerebral blood flow (rCBF) alterations. Animal studies suggest that the normalisation of glutamate levels decreases rCBF and prevents structural changes in hippocampus. However, the relationship between glutamate and rCBF in anterior cingulate cortex (ACC) of humans has not been studied in the absence of an…
No prominent works on this page.
Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers
Progressive loss of brain tissue is seen in some patients with schizophrenia and might be caused by increased levels of glutamate and resting cerebral blood flow (rCBF) alterations. Animal studies suggest that the normalisation of glutamate levels decreases rCBF and prevents structural changes in hippocampus. However, the relationship between glutamate and rCBF in anterior cingulate cortex (ACC) of humans has not been studied in the absence of an…
No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis—A Randomized Clinical Trial
ClinicalTrials.gov, identifier NCT02098408
European Validation of the Self-Evaluation of Negative Symptoms (SNS)
In a large European multicentric sample, this study demonstrated that the SNS has: (1) good psychometric properties with good convergent and divergent validities; (2) a five-factor latent structure; (3) an association with patients' functional outcome; and (4) the capacity to identify subjects with negative symptoms that is close to the BNSS and superior to the PANSS negative subscale
Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the Amend Trial Protocol
[ClinicalTrials.gov], identifier [NCT04789915]
Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
Patients treated with aripiprazole improved on negative symptoms, which was not the case for patients treated with amisulpride. This may point to a general effect of a partial D2 receptor agonist on negative symptoms in patients with first-episode psychoses. There was, however, no improvement in cognitive functions
Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia
Our results indicate that pathways to functional outcomes are specific for different domains of real-life functioning and that negative symptoms and social cognition mediate the impact of neurocognitive deficits on different domains of functioning. Our results suggest that both negative symptoms and social cognition should be targeted by psychosocial interventions to enhance the functional impact of neurocognitive remediation
Medicine (6 works) · Psychology (6 works) · Cognition (4 works) · Internal Medicine (4 works) · Psychiatry (4 works) · Schizophrenia research and treatment (4 works) · Clinical Psychology (3 works) · Clinical Psychology (3 works) · Neuroscience (3 works) · Schizophrenia (object-oriented programming (3 works)